# Signals Article: Putative Target P98161 for Autosomal Dominant Polycystic Kidney Disease
Background
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the progressive development of numerous cysts in the kidneys, leading to kidney enlargement and eventual loss of kidney function. It is one of the most common inherited kidney diseases and can result in significant morbidity and mortality. Despite advances in understanding the genetic basis of ADPKD, effective treatments remain limited, highlighting the need for novel therapeutic targets.
Data-mining rationale
In a recent reanalysis effort, UniProt entry P98161 was identified as a putative target for ADPKD. This candidate emerged from cross-referencing UniProt's reviewed human entries with expression-profiling studies in the NCBI GEO database, specifically datasets GDS:200074453, GDS:200074452, GDS:200074451, GDS:200072554, and GDS:200075578. Although P98161 is present in these studies, it has not been associated with any registered Phase 1 or higher clinical programs, suggesting its potential as an unexplored target.
Why prior analyses may have missed this
Many of the GEO datasets containing P98161 predate modern empirical-Bayes statistical methods, such as limma, which are crucial for accurate differential expression analysis. The absence of proper multiple-testing correction in earlier analyses may have led to the underestimation of P98161's potential as a target for ADPKD. Additionally, the lack of integration with pathway and tissue-specific databases may have obscured its relevance.
Reasoning for further validation
To fully assess the potential of P98161 as a target for ADPKD, several steps are recommended. Re-analyzing the matched GEO datasets using limma with Benjamini-Hochberg FDR correction will provide a more accurate picture of differential expression. Validation of top differentially-expressed genes by qPCR in an independent cohort is essential to confirm findings. Checking tissue specificity in GTEx and the Human Protein Atlas will help determine the target's relevance in the context of ADPKD. Running pathway analyses using STRING or OmniPath will provide insights into the biological context of P98161. If validated, assessing the druggability of P98161 via DGIdb and ChEMBL will be crucial for potential therapeutic development.